SCHEMBL1920963

SCHEMBL1920963

Clc1ccc(CN2CCC(Nc3ncnc4sc5c(c34)CCCC5)CC2)cc1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.82
MKNK1 Q9BUB5 3/20 0.59
RAB9A P51151 2/20 0.56
RXFP1 Q9HBX9 2/20 0.56
HTT P42858 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
KMT2A Q03164 2/20 0.56
MAPK1 P28482 1/20 0.56
IRAK4 Q9NWZ3 1/20 0.55
LMNA P02545 3/20 0.54
NOD2 Q9HC29 1/20 0.54
HTR2B P41595 1/20 0.51
PDE5A O76074 1/20 0.49
MAPT P10636 1/20 0.49
EGFR P00533 1/20 0.48
PTGS2 P35354 1/20 0.48
FGFR1 P11362 1/20 0.48
GAA P10253 1/20 0.48
TSHR P16473 1/20 0.48
AKT2 P31751 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1605200 0.92 MEN1 (0.96) MEN1MKNK1RAB9ARXFP1HTT
SCHEMBL12734237 0.91 MEN1 (0.80) MEN1MKNK1RAB9ARXFP1HTT
SCHEMBL1651778 0.91 MEN1 (0.80) MEN1MKNK1RAB9ARXFP1HTT
SCHEMBL1604254 0.91 MEN1 (0.80) MEN1MKNK1RAB9ARXFP1HTT
SCHEMBL10343392 0.90 MEN1 (1.00) MEN1MKNK1RAB9ARXFP1HTT
SCHEMBL1654043 0.89 MEN1 (0.76) MEN1MKNK1RAB9ARXFP1HTT
SCHEMBL1652468 0.89 MEN1 (0.76) MEN1MKNK1RAB9ARXFP1HTT
SCHEMBL12533503 0.87 MEN1 (0.73) MEN1RAB9ARXFP1HTTSMN1; SMN2
SCHEMBL1651515 0.86 MEN1 (0.73) MEN1RAB9ARXFP1HTTSMN1; SMN2
SCHEMBL1920737 0.86 MEN1 (0.78) MEN1RAB9ARXFP1HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1622914-B1 NEW PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS TROVIS PHARMACEUTICALS LLC (US) 2011-06-01 EP disclosed
EP-1622914-B1 NEW PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS TROVIS PHARMACEUTICALS LLC (US) 2011-06-01 EP disclosed
EP-1622914-A4 NEW PIPERIDINYLAMINO-THIENO 2,3-D PYRIMIDINE COMPOUNDS EPIX DELAWARE INC (US) 2008-03-12 EP disclosed
US-7030240-B2 5-HT receptor antagonist; [1-(2-Fluoro-benzyl)-piperidin-4-yl]-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-amine; treating vascular disorders, angina, migraine, pulmonary hypertension and systemic hypertension PREDIX PHARMACEUTICALS HOLDINGS, INC. (US) 2006-04-18 US disclosed
EP-1622914-A2 NEW PIPERIDINYLAMINO-THIENO 2,3-D PYRIMIDINE COMPOUNDS Predix Pharmaceuticals Holdings, Inc. (US) 2006-02-08 EP disclosed
US-20040248904-A1 New piperidinylamino-thieno[2,3-d] pyrimidine compounds TROVIS PHARMACEUTICALS, LLC 2004-12-09 US disclosed
WO-2004089312-A2 NEW PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS PREDIX PHARMACEUTICALS HOLDINGS, INC. (US) 2004-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248904-A1 New piperidinylamino-thieno[2,3-d] pyrimidine compounds HTR5A, HTR2C, HTR1A MEN1 2833/4885MKNK1 2886/4885RAB9A 1598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.